Keywords
Edema macular
Facoemulsificación
Nepafenac
Cirugía de catarata
Inflamación Anti Inflammatory agents
Non steroidal
Macular edema
Phacoemulsification
Nepafenac
Cataract surgery
Inflammation
How to Cite
Abstract
Purpose: to compare total macular volume (TMV), retinal thickness, best spectacle-corrected visual acuity (BSCVA) and the incidence of post-cataract surgery macular edema, in eyes treated with nepafenac 0,1%, dexamethasone 0,1% or a combination of the two. Methods: randomized, controlled, observer-masked, prospective study. 147 eyes with cataract were randomized to receive dexamethasone 0,1% qid for 12 days postoperatively, nepafenac 0,1% tid two days prior and 15 days postoperatively or the combination of the two. End point measures were intraoperative miosis, anterior chamber cells, intraocular pressure (IOP) at 1 and 6 weeks; BSCVA after surgery, TMV, foveal and perifoveal thickness (measured by OCT) and the presence or absence of macular edema (foveal thickness > 240 microns) at 6 weeks. Results: baseline characteristics were similar among the three groups. The dexamethasone group developed more intraoperative miosis versus the nepafenac group (p0.05). Conclusions: the three groups were similarly effective to control postoperative inflammation. However, the nepafenac group consistently showed less retinal thickening, less IOP in the first week and less intraoperative miosis.
References
Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557-634.
Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007 Sep;33(9):1550-1558. https://doi.org/10.1016/j.jcrs.2007.05.013
Stewart R, Grosserode R, Cheetham JK, Rosenthal A. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Clin Ther. 1999 Abr;21(4):723-732. https://doi.org/10.1016/S0149-2918(00)88323-X
Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007 Sep;33(9):1539-1545. https://doi.org/10.1016/j.jcrs.2007.05.015
Deschenes J, Murray PI, Rao NA, Nussenblatt RB. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul. Immunol. Inflamm. 2008;16:1-2. https://doi.org/10.1080/09273940801899822
Kim SJ, Belair M-L, Bressler NM, Dunn JP, Thorne JE, Kedhar SR, et al. A method of reporting macular edema after cataract surgery using optical coherence tomography. Retina (Philadelphia, Pa.). 2008;28:870-876. https://doi.org/10.1097/IAE.0b013e318169d04e
Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007;33:53-58. https://doi.org/10.1016/j.jcrs.2006.08.043
Nardi M, Lobo C, Bereczki A, Cano J, Zagato E, Potts S, et al. Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery. Clin Ophthalmol. 2007 ;1:527-533.
Asano S, Miyake K, Ota I, Sugita G, Kimura W, Sakka Y, et al. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after smallincision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. J Cataract Refract Surg. 2008;34:57-63. https://doi.org/10.1016/j.jcrs.2007.08.030
Miyanaga M, Miyai T, Nejima R, Maruyama Y, Miyata K, Kato S. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmol. 2009;87:300-305. https://doi.org/10.1111/j.1755-3768.2008.01433.x
Ray S, D'Amico DJ. Pseudophakic cystoid macular edema. Semin Ophthalmol. 2002;17:167-80. https://doi.org/10.1076/soph.17.3.167.14794
Guzek JP, Holm M, Cotter JB, Cameron JA, Rademaker WJ, Wissinger DH, et al. Risk factors for intraoperative complications in 1000 extracapsular cataract cases. Ophthalmology. 1987;94:461-466. https://doi.org/10.1016/S0161-6420(87)33424-4
Solomon KD, Turkalj JW, Whiteside SB, Stewart JA, Apple DJ. Topical 0.5% ketorolac vs 0.03% flurbiprofen for inhibition of miosis during cataract surgery. Arch. Ophthalmol. 1997;115:1119-1122. https://doi.org/10.1001/archopht.1997.01100160289004
Antcliff RJ, Trew DR. The maintenance of per-operative mydriasis in phacoemulsification with topical diclofenac sodium. Eye (Lond). 1997;11 ( Pt 3):389-391. https://doi.org/10.1038/eye.1997.82
Cervantes-Coste G, Sánchez-Castro YG, OrozcoCarroll M, Mendoza-Schuster E, Velasco-Barona C. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clin Ophthalmol. 2009;3:219-226. https://doi.org/10.2147/OPTH.S4820
Donnenfeld ED, Perry HD, Wittpenn JR, Solomon R, Nattis A, Chou T. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg. 2006;32:1474-1482. https://doi.org/10.1016/j.jcrs.2006.04.009
Yavas GF, Oztürk F, Küsbeci T. Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. J Cataract Refract Surg. 2007;33:804-807. https://doi.org/10.1016/j.jcrs.2007.01.033
Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch. Ophthalmol. 2006;124:193-198. https://doi.org/10.1001/archopht.124.2.193
Wexler A, Sand T, Elsås TB. Macular thickness measurements in healthy Norwegian volunteers: an optical coherence tomography study. BMC Ophthalmol. 2010;10:13. https://doi.org/10.1186/1471-2415-10-13
Biro Z, Balla Z, Kovacs B. Change of foveal and perifoveal thickness measured by OCT after phacoemulsification and IOL implantation. Eye (Lond). 2008;22:8-12. https://doi.org/10.1038/sj.eye.6702460
Perente I, Utine CA, Ozturker C, Cakir M, Kaya V, Eren H, et al. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Curr. Eye Res. 2007;32:241- 247. https://doi.org/10.1080/02713680601160610
Degenring RF, Vey S, Kamppeter B, Budde WM, Jonas JB, Sauder G. Effect of uncomplicated phacoemulsification on the central retina in diabetic and non-diabetic subjects. Graefes Arch. Clin. Exp. Ophthalmol. 2007;245:18-23. https://doi.org/10.1007/s00417-006-0377-4